A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Guillen, Katrin P.; Fujita, Maihi; Butterfield, Andrew J.; Scherer, Sandra D.; Bailey, Matthew H.; Chu, Zhengtao; DeRose, Yoko S.; Zhao, Ling; Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Toner, Jennifer; Wang, Guoying; Qiao, Yi; Huang, Xiaomeng; Greenland, Jeffery A.; Vahrenkamp, Jeffery M.; Lum, David H.; Factor, Rachel E.; Nelson, Edward W.; Matsen, Cindy B.; Poretta, Jane M.; Rosenthal, Regina; Beck, Anna C.; Buys, Saundra S.; Vaklavas, Christos; Ward, John H.; Jensen, Randy L.; Jones, Kevin B.; Li, Zheqi; Oesterreich, Steffi; Dobrolecki, Lacey E.; Pathi, Satya S.; Woo, Xing Yi; Berrett, Kristofer C.; Wadsworth, Mark E.; Chuang, Jeffrey H.; Lewis, Michael T.; Marth, Gabor T.; Gertz, Jason; Varley, Katherine E.; Welm, Bryan E.; Welm, Alana L.

doi:10.1038/s43018-022-00337-6

Cited by 420Cancer Cells and MetastasisBreast Cancer Treatment Studies3D Printing in Biomedical Research

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Open access

Guillen, Katrin P., Fujita, Maihi, Butterfield, Andrew J., Scherer, Sandra D., Bailey, Matthew H., Chu, Zhengtao, DeRose, Yoko S., Zhao, Ling +34 more·2022·Nature Cancer

DOI 10.1038/s43018-022-00337-6PMC PMC8882468

Open this paper in CoChat — free account

Abstract

Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures from tumors that represent the greatest unmet need: endocrine-resistant, treatment-refractory and metastatic breast cancers. We leverage matched PDXs and PDX-derived organoids (PDxO) for drug screening that is feasible and cost-effective with in vivo validation. Moreover, we demonstrate the feasibility of using these models for precision oncology in real time with clinical care in a case of triple-negative breast cancer (TNBC) with early metastatic recurrence. Our results uncovered a Food and Drug Administration (FDA)-approved drug with high efficacy against the models. Treatment with this therapy resulted in a complete response for the individual and a progression-free survival (PFS) period more than three times longer than their previous therapies. This work provides valuable methods and resources for functional precision medicine and drug development for human breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s43018-022-00337-6

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Matano and colleagues found that benign human intestinal organoids carrying mutations in 1-2 genes could not form tumors, while more malignant ones with mutations in 4-5 genes were tumorigenic.
“They found that benign organoids carrying mutations in 1–2 genes could not form tumors while more malignant ones with mutations in 4–5 genes were tumorigenic173.”
From Organoids (2022) · cites this paper as [173]
The Introduction and Results passages describe breast cancer-derived organoid and xenograft models, not benign human intestinal organoids. Searches for Matano, intestinal organoids, and the claimed 1–2 versus 4–5 gene mutation comparison found no passage in our copy addressing that finding. (LLM, conf=0.76)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · see citing works
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · see citing works
Self-citation
Integrative genomics viewer
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · see citing works
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · see citing works
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174 · see citing works
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,122 · see citing works
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434 · see citing works
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099 · see citing works
SIFT: predicting amino acid changes that affect protein function
Ng, P. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg509 · Cited by 6,601 · see citing works
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777 · see citing works
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,737 · see citing works
Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression
Hafemeister, C., & Satija, R. (2019) · Genome Biology · doi:10.1186/s13059-019-1874-1 · Cited by 4,479 · see citing works
ClinVar: improving access to variant interpretations and supporting evidence
Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1153 · Cited by 4,196 · see citing works
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659 · see citing works
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256 · see citing works
Self-citation
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · see citing works
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · see citing works
Allele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,231 · see citing works
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
DeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M., Factor, R. E., Matsen, C. B., Milash, B. A., Nelson, E. W., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,006 · see citing works
Self-citation
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R. C., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M. A., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 938 · see citing works
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A. Y., Eyob, H., Balakrishnan, S., Wang, C., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 894 · see citing works
Pathogenic Germline Variants in 10,389 Adult Cancers
Huang, K., Mashl, R. J., Wu, Y., Ritter, D., Wang, J., Oh, C., Paczkowska, M., Reynolds, S. M., Wyczalkowski, M. A., Oak, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.039 · Cited by 838 · see citing works
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Massard, C., Michiels, S., Ferté, C., Deley, M. L., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E. E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783 · see citing works
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
Herrera-Abreu, M. T., Palafox, M., Asghar, U. S., Rivas, M. A., Cutts, R. J., García-Murillas, I., Pearson, A., Guzmán, M., Rodríguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 768 · see citing works
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Veroli, G. Y. D., Fornari, C., Wang, D. Y. Q., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736 · see citing works
Patient-derived xenografts undergo mouse-specific tumor evolution
Ben-David, U., Ha, G., Tseng, Y.-Y., Greenwald, N. F., Oh, C., Shih, J., McFarland, J. M., Wong, B., Boehm, J. S., Beroukhim, R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3967 · Cited by 716 · see citing works
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681 · see citing works
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D., Amant, F. C., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budínská, E., Caldas, C., Chang, D. K.-F., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.140 · Cited by 663 · see citing works
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Li, S., Shen, D., Shao, J., Crowder, R. J., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 623 · see citing works
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Berger, A. C., Korkut, A., Kanchi, R. S., Hegde, A. M., Lenoir, W. F., Liu, W., Liu, Y., Fan, H., Shen, H., Ravikumar, V., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.014 · Cited by 606 · see citing works
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery
Weeber, F., Ooft, S., Dijkstra, K. K., & Voest, E. E. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.06.012 · Cited by 486 · see citing works
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
Bruna, A., Rueda, O. M., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N., McNamara, K. L., Sandoval, J. L., Cassidy, J. W., Vidaković, A. T., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.041 · Cited by 433 · see citing works
Self-citation
Xenograft and organoid model systems in cancer research
Bleijs, M., van de Wetering, M., Clevers, H., & Drost, J. (2019) · The EMBO Journal · doi:10.15252/embj.2019101654 · Cited by 400 · see citing works
Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
Wang, M., Yao, L., Cheng, M., Cai, D., Martínek, J., Pan, C.-X., Shi, W., Ma, A., White, R. D., Airhart, S. D., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700740r · Cited by 338 · see citing works
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns
Holm, K., Hegardt, C., Staaf, J., Vallon‐Christersson, J., Jonsson, G. G., Olsson, H. L., Borg, Å., & Ringnér, M. (2010) · Breast Cancer Research · doi:10.1186/bcr2590 · Cited by 306 · see citing works
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Kato, S., Kim, K. H., Lim, H. J., Boichard, A., Nikanjam, M., Weihe, E., Kuo, D. J., Eskander, R. N., Goodman, A. M., Galanina, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18613-3 · Cited by 295 · see citing works
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S., Alférez, D., Aparicio, S. A. J. R., Behbod, F., Bentires‐Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 261 · see citing works
Self-citation
Patient‐Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine
DeRose, Y. S., Gligorich, K. M., Wang, G., Georgelas, A., Bowman, P., Courdy, S., Welm, A. L., & Welm, B. E. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1423s60 · Cited by 227 · see citing works
Self-citation
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Wang, P., Bahreini, A., Gyanchandani, R., Lucas, P. C., Hartmaier, R. J., Watters, R. J., Jonnalagadda, A. R., Bittar, H. E. T., Berg, A., Hamilton, R. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1534 · Cited by 200 · see citing works
Self-citation
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges
Herzog, S. K., & Fuqua, S. A. W. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01564-x · Cited by 192 · see citing works
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190 · see citing works
Self-citation
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
Benetatos, C. A., Mitsuuchi, Y., Burns, J. M., Neiman, E. M., Condon, S. M., Yu, G., Seipel, M. E., Kapoor, G. S., LaPorte, M. G., Rippin, S. R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0798 · Cited by 179 · see citing works
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
Capasso, A., Lang, J., Pitts, T. M., Jordan, K. R., Lieu, C. H., Davis, S. L., Diamond, J. R., Kopetz, S., Barbee, J., Peterson, J. N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0518-z · Cited by 178 · see citing works
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J. M., & Piccart, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 177 · see citing works
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
Bahreini, A., Li, Z., Wang, P., Levine, K. M., Tasdemir, N., Cao, L., Weir, H. M., Puhalla, S. L., Davidson, N. E., Stern, A. M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0851-4 · Cited by 162 · see citing works
Self-citation
Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies
Condon, S. M., Mitsuuchi, Y., Deng, Y., LaPorte, M. G., Rippin, S. R., Haimowitz, T., Alexander, M. D., Kumar, P. T., Hendi, M. S., Lee, Y.-H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500176w · Cited by 153 · see citing works
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
Ryan, J. A., Montero, J., Rocco, J. W., & Letai, A. G. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0107 · Cited by 129 · see citing works
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
Tokheim, C. J., & Karchin, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.005 · Cited by 126 · see citing works
High-throughput imaging: Focusing in on drug discovery in 3D
Li, L., Zhou, Q., Voss, T. C., Quick, K. L., & LaBarbera, D. V. (2015) · Methods · doi:10.1016/j.ymeth.2015.11.013 · Cited by 125 · see citing works
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
Montaudon, É., Nikitorowicz-Buniak, J., Sourd, L., Morisset, L., Botty, R. E., Huguet, L., Dahmani, A., Painsec, P., Némati, F., Vacher, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17697-1 · Cited by 122 · see citing works
Identification of Novel High-Frequency DNA Methylation Changes in Breast Cancer
Ordway, J. M., Budiman, M. A., Korshunova, Y. O., Maloney, R. K., Bedell, J. A., Citek, R. W., Bacher, B., Peterson, S., Rohlfing, T., Hall, J. A., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001314 · Cited by 110 · see citing works
Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse
du Manoir, S., Orsetti, B., Bras-Gonçalves, R., Nguyen, T.-T., Lasorsa, L., Boissière‐Michot, F., Massemin, B., Colombo, P., Bibeau, F., Jacot, W., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.010 · Cited by 72 · see citing works
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial
Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8392 · Cited by 72 · see citing works
Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine
Gabriel, M. T., Cochonneau, D., Cadé, M., Jubelin, C., Heymann, M., & Heymann, D. (2018) · Cancers · doi:10.3390/cancers11010019 · Cited by 67 · see citing works
Applicability of drug response metrics for cancer studies using biomaterials
Brooks, E. A., Galarza, S., Gencoglu, M. F., Cornelison, R. C., Munson, J. M., & Peyton, S. R. (2019) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2018.0226 · Cited by 67 · see citing works
Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis
Schneeberger, V. E., Allaj, V., Gardner, E. E., Poirier, J. T., & Rudin, C. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160587 · Cited by 62 · see citing works
Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis
Evrard, Y. A., Srivastava, A., Randjelović, J., Arunachalam, S., Bult, C. J., Chen, H., Chen, L., Davies, M., Davies, S., Davis‐Dusenbery, B. N., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3101 · Cited by 59 · see citing works
Self-citation
Targeting triple-negative breast cancers with the Smac-mimetic birinapant
Lalaoui, N., Merino, D., Giner, G., Vaillant, F., Chau, D., Liu, L., Kratina, T., Pal, B., Whittle, J. R., Etemadi, N., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0541-0 · Cited by 51 · see citing works
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50 · see citing works
Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells
Stack, G., Kumar, V., Green, S., Ponglikitmongkol, M., Berry, M., Rio, M., Nunez, A. M., Roberts, M., Koehl, C., Bellocq, P., et al. (1988) · Cancer treatment and research · doi:10.1007/978-1-4613-1733-3_8 · Cited by 44 · see citing works
Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts
Byrne, A. T., Alférez, D., Amant, F. C., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budínská, E., Caldas, C., Chang, D. K.-F., et al. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.85 · Cited by 37 · see citing works
An Immunohistochemical Method to Study Breast Cancer Cell Subpopulations and Their Growth Regulation by Hormones in Three-Dimensional Cultures
Pinto, M. P., Jacobsen, B. M., & Horwitz, K. B. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00015 · Cited by 36 · see citing works
Targeted mutation detection in breast cancer using MammaSeq™
Smith, N. G., Gyanchandani, R., Shah, O. S., Gurda, G. T., Lucas, P. C., Hartmaier, R. J., Brufsky, A., Puhalla, S., Bahreini, A., Kota, K. J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1102-7 · Cited by 36 · see citing works
Self-citation
Urinary Retention and Cystitis Associated with Subcutaneous Estradiol Pellets in Female Nude Mice
Pearse, G., Frith, J., Randall, K. J., & Klinowska, T. C. M. (2009) · Toxicologic Pathology · doi:10.1177/0192623308329281 · Cited by 32 · see citing works
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
Xie, X., Lee, J., Liu, H., Pearson, T., Lu, A., Tripathy, D., Devi, G. R., Bartholomeusz, C., & Ueno, N. T. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1160 · Cited by 32 · see citing works
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
Pezo, R. C., Chen, T. W., Berman, H. K., Mulligan, A. M., Razak, A. A., Siu, L. L., Cescon, D. W., Amir, E., Elser, C., Warr, D. G., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4580-2 · Cited by 25 · see citing works
Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate Corynebacterium bovis.
Manuel, C. A., Bagby, S. M., Reisinger, J., Pugazhenthi, U., Pitts, T. M., Keysar, S. B., Arcaroli, J. J., & Leszczynski, J. K. (2017) · Europe PMC (PubMed Central) · Cited by 11 · see citing works
Assays for functionally defined normal and malignant mammary stem cells
Aalam, S. M. M., Beer, P. A., & Kannan, N. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.004 · Cited by 3 · see citing works

Flagged first, then by citations

Research works printed but not linked: 2

[32]Bruna A A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell 167, 260– 274.e222, doi: 10.1016/j.cell.2016.08.041 (2016). 27641504 PMC5037319 · DOI
[48]Carlson JA, G. R, Compton SR, Zeiss C, Uchio E.. Poliomyelitis in SCID Mice Following Injection of Basement Membrane Matrix Contaminated with Lactate Dehydrogenase-elevating Virus.. Proceedings of the 59th AALAS National Meeting, PS35: 9–13 November 2008, Indianapolis. (2008).

Sorted by citations

Organoids
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,001 · see citing works
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 524 · see citing works
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 351 · see citing works
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 337 · see citing works
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations
Letai, A. G., Bhola, P. D., & Welm, A. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 282 · see citing works
Self-citation
Organoids: The current status and biomedical applications
Yang, S., Hu, H., Kung, H., Zou, R.-Q., Dai, Y.-S., Hu, Y.-F., Wang, T., Lv, T., Yu, J., & Li, F. (2023) · MedComm · doi:10.1002/mco2.274 · Cited by 282 · see citing works
Recent advances and clinical translation of liposomal delivery systems in cancer therapy
Chen, J., Hu, S., Sun, M., Shi, J., Zhang, H., Yu, H., & Yang, Z. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106688 · Cited by 229 · see citing works
Drug screening at single-organoid resolution via bioprinting and interferometry
Tebon, P. J., Wang, B., Markowitz, A. L., Davarifar, A., Tsai, B. L., Krawczuk, P., Gonzalez, A. E., Sartini, S., Murray, G. F., Nguyen, H. T. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38832-8 · Cited by 161 · see citing works
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 149 · see citing works
Acquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 145 · see citing works
Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025
Allgayer, H., Mahapatra, S., Mishra, B., Swain, B., Saha, S., Khanra, S., Kumari, K., Panda, V. K., Malhotra, D., Patil, N. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02338-2 · Cited by 127 · see citing works
Transferred mitochondria accumulate reactive oxygen species, promoting proliferation
Kidwell, C. U., Casalini, J. R., Pradeep, S., Scherer, S. D., Greiner, D., Bayık, D., Watson, D. C., Olson, G. S., Lathia, J. D., Johnson, J. S., et al. (2023) · eLife · doi:10.7554/elife.85494 · Cited by 111 · see citing works
Self-citation
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
Salemme, V., Centonze, G., Avalle, L., Natalini, D., Piccolantonio, A., Arina, P., Morellato, A., Ala, U., Taverna, D., Turco, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170264 · Cited by 106 · see citing works
Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics
Bhatia, S., Kramer, M., Russo, S., Naik, P., Arun, G., Brophy, K., Andrews, P., Fan, C., Perou, C. M., Preall, J. B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2807 · Cited by 103 · see citing works
Data analysis guidelines for single-cell RNA-seq in biomedical studies and clinical applications
Su, M., Pan, T., Chen, Q.-Z., Zhou, W., Gong, Y., Xu, G., Yan, H.-Y., Li, S., Shi, Q.-Z., Zhang, Y., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00434-8 · Cited by 103 · see citing works
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine
Yao, Q., Cheng, S., Pan, Q., Yu, J., Cao, G., Li, L., & Cao, H. (2024) · MedComm · doi:10.1002/mco2.735 · Cited by 97 · see citing works
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment
Tosca, E. M., Ronchi, D., Facciolo, D., & Magni, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041058 · Cited by 96 · see citing works
Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine
Derouane, F., van Marcke, C., Berlière, M., Gerday, A., Fellah, L., Leconte, I., Bockstal, M. V., Galant, C., Corbet, C., & Duhoux, F. P. (2022) · Cancers · doi:10.3390/cancers14163876 · Cited by 89 · see citing works
Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 90 · see citing works
Complex in vitro model: A transformative model in drug development and precision medicine
Wang, L., Hu, D., Xu, J., Hu, J., & Wang, Y. (2023) · Clinical and Translational Science · doi:10.1111/cts.13695 · Cited by 87 · see citing works
Untangling the web of intratumour heterogeneity
Li, Z., Seehawer, M., & Polyák, K. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00969-x · Cited by 81 · see citing works
Self-citation
Role of Patient-Derived Models of Cancer in Translational Oncology
Idrisova, K., Simon, H., & Gomzikova, M. O. (2022) · Cancers · doi:10.3390/cancers15010139 · Cited by 81 · see citing works
Patient‐derived xenograft model in cancer: establishment and applications
Gu, A., Li, J., Li, M., & Liu, Y. (2025) · MedComm · doi:10.1002/mco2.70059 · Cited by 79 · see citing works
The landscape of drug sensitivity and resistance in sarcoma
Shihabi, A. A., Tebon, P. J., Nguyen, H. T. L., Chantharasamee, J., Sartini, S., Davarifar, A., Jensen, A. Y., Diaz-Infante, M. B., Cox, H., Gonzalez, A. E., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.08.010 · Cited by 75 · see citing works
GelMA, Click-Chemistry Gelatin and Bioprinted Polyethylene Glycol-Based Hydrogels as 3D Ex Vivo Drug Testing Platforms for Patient-Derived Breast Cancer Organoids
Bock, N., Forouz, F., Hipwood, L., Clegg, J., Jeffery, P. L., Gough, M., van Wyngaard, T., Pyke, C., Adams, M. N., Bray, L. J., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010261 · Cited by 73 · see citing works
Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies
Zhou, Z., Pang, Y., Ji, J., He, J., Liu, T., Ouyang, L., Zhang, W., Zhang, X., Zhang, Z., Zhang, K., et al. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00896-4 · Cited by 73 · see citing works
From 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research
Rauner, G., Gupta, P. B., & Kuperwasser, C. (2025) · Nature Methods · doi:10.1038/s41592-025-02769-1 · Cited by 73 · see citing works
Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses
Ramos Zapatero, M., Tong, A., Opzoomer, J. W., O’Sullivan, R., Cardoso Rodriguez, F., Sufi, J., Vlckova, P., Nattress, C., Qin, X., Claus, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.11.005 · Cited by 72 · see citing works
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
Schade, A. E., Perurena, N., Yang, Y., Rodriguez, C. L., Krishnan, A., Gardner, A., Loi, P., Xu, Y., Nguyen, V. T. M., Mastellone, G. M., et al. (2024) · Nature · doi:10.1038/s41586-024-08031-6 · Cited by 72 · see citing works
Self-citation
Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models
Wang, E., Xiang, K., Zhang, Y., & Wang, X. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 71 · see citing works
EMT and cancer: what clinicians should know
Thompson, E. W., Redfern, A. D., Brabletz, S., Berx, G., Agarwal, V., Ganesh, K., Huang, R. Y., Ishay-Ronen, D., Savagner, P., Sheng, G., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01058-2 · Cited by 70 · see citing works
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04841-w · Cited by 65 · see citing works
Patient‐derived xenograft models in pan‐cancer: From bench to clinic
Li, J., Gu, A., Tang, N., Zengin, G., Li, M., & Liu, Y. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250016 · Cited by 62 · see citing works
The role of organoids in cancer research
Fang, Z., Li, P., Du, F., Shang, L., & Li, L. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00433-y · Cited by 61 · see citing works
3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy
Zhu, Y., Kang, E., Wilson, M., Basso, T., Chen, E., Yu, Y., & Li, Y.-R. (2022) · Organoids · doi:10.3390/organoids1020012 · Cited by 60 · see citing works
Exploring the interaction between extracellular matrix components in a 3D organoid disease model to replicate the pathophysiology of breast cancer
Bhattacharya, A., Alam, K., Roy, N. S., Kaur, K., Kaity, S., Ravichandiran, V., & Roy, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02926-4 · Cited by 59 · see citing works
Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer
Polanco, E. R., Moustafa, T. E., Butterfield, A., Scherer, S. D., Cortes-Sanchez, E., Bodily, T. A., Spike, B. T., Welm, B. E., Bernard, P. S., & Zangle, T. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03759-1 · Cited by 56 · see citing works
Self-citation
Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
Sflomos, G., Schipper, K., Koorman, T., Fitzpatrick, A., Oesterreich, S., Lee, A. V., Jonkers, J., Brunton, V. G., Christgen, M., Isacke, C. M., et al. (2021) · Cancers · doi:10.3390/cancers13215396 · Cited by 51 · see citing works
Self-citation
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
Wu, S., Jin, X., Liu, Y., Wang, Z.-Y., Zuo, W., Ma, D., Xiao, Y., Fu, T., Xiao, Y.-L., Chen, L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03776-7 · Cited by 51 · see citing works
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Lin, C.-C. A., Chang, T.-C., Wang, Y., Guo, L. M., Gao, Y., Bikorimana, E., Lemoff, A. S., Fang, Y. V., Zhang, H., Zhang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46495-2 · Cited by 48 · see citing works
Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions
Wang, S., Wu, W., Lin, X., Zhang, K. M., Wu, Q., Luo, M., & Zhou, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01171-8 · Cited by 47 · see citing works
An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer
Scherer, S. D., Riggio, A. I., Haroun, F., DeRose, Y. S., Ekiz, H. A., Fujita, M., Toner, J., Zhao, L., Li, Z., Oesterreich, S., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01476-x · Cited by 43 · see citing works
Self-citation
Advancing cancer research through organoid technology
Zeng, G., Yu, Y., Wang, M., Liu, J., He, G., Yu, S., Yan, H., Yang, L., Li, H., & Peng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05824-1 · Cited by 43 · see citing works
FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer
Casalino, L., Talotta, F., Matino, I., & Verde, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098307 · Cited by 42 · see citing works
Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice
Chen, A., Neuwirth, I., & Herndler‐Brandstetter, D. (2023) · Cancers · doi:10.3390/cancers15112989 · Cited by 42 · see citing works
Mammary Glands of Women, Female Dogs and Female Rats: Similarities and Differences to Be Considered in Breast Cancer Research
Ferreira, T., Gama, A., Seixas, F., Faustino‐Rocha, A. I., Lopes, C., Gaspar, V. M., Mano, J. F., Medeiros, R., & Oliveira, P. A. (2023) · Veterinary Sciences · doi:10.3390/vetsci10060379 · Cited by 41 · see citing works
Organoids: opportunities and challenges of cancer therapy
Jiang, X., Oyang, L., Qiu, P., Liu, Q., Xu, X., Wu, N., Tan, S., Yang, W., Han, Y., Lin, J., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232528 · Cited by 41 · see citing works
Patient-derived xenograft models: Current status, challenges, and innovations in cancer research
Liu, M., & Yang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101520 · Cited by 44 · see citing works
OBSERVE: guidelines for the refinement of rodent cancer models
Vleeschauwer, S. I. D., van de Ven, M., Oudin, A., Debusschere, K., Connor, K., Byrne, A. T., Ram, D., Rhebergen, A. M., Raeves, Y. D., Dahlhoff, M., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-00998-w · Cited by 40 · see citing works
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer
Truong, T. H., Benner, E., Hagen, K. M., Temiz, N. A., Kerkvliet, C. J. P., Wang, Y., Cortes-Sanchez, E., Yang, C.-H., Trousdell, M. C., Pengo, T., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01871-w · Cited by 39 · see citing works
Self-citation
In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts
Souto, E. P., Dobrolecki, L. E., Villanueva, H. J., Sikora, A. G., & Lewis, M. T. (2022) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-022-09520-y · Cited by 38 · see citing works
Self-citation
Functional Drug Screening in the Era of Precision Medicine
Napoli, G. C., Figg, W. D., & Chau, C. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.912641 · Cited by 38 · see citing works
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38 · see citing works
PDX models for functional precision oncology and discovery science
Blanchard, Z., Brown, E. A., Ghazaryan, A., & Welm, A. L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00779-3 · Cited by 38 · see citing works
Self-citation
Organoid‐Guided Precision Medicine: From Bench to Bedside
Tao, B., Li, X., Hao, M., Tian, T., Li, Y., Li, X., Yang, C., Li, Q., Feng, Q., Zhou, H., et al. (2025) · MedComm · doi:10.1002/mco2.70195 · Cited by 38 · see citing works
Self-citation
O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer
Zhang, Y., Zhou, S., Kai, Y., Zhang, Y.-Q., Peng, C., Li, Z., Jameel, M., Belmar, J., Zheng, X., Ma, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49875-w · Cited by 37 · see citing works
Self-citation
Circulating tumor cell-derived preclinical models: current status and future perspectives
Kahounová, Z., Pícková, M., Drápela, S., Bouchal, J., Szczyrbová, E., Navrátil, J., & Souček, K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06059-6 · Cited by 37 · see citing works
Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Fisher, N. C., Byrne, R. M., Leslie, H., Wood, C. S., Legrini, A., Cameron, A. J., Ahmaderaghi, B., Corry, S. M., Malla, S. B., Amirkhah, R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1102 · Cited by 36 · see citing works
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Hynds, R. E., Huebner, A., Pearce, D. R., Hill, M. S., Akarca, A. U., Moore, D. A., Ward, S., Gowers, K. H. C., Karasaki, T., Bakir, M. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47547-3 · Cited by 36 · see citing works
Self-citation
A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses
Raffo‐Romero, A., Ziane-Chaouche, L., Salomé‐Desnoulez, S., Hajjaji, N., Fournier, I., Salzet, M., & Duhamel, M. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100792 · Cited by 36 · see citing works
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
Petrosyan, V., Dobrolecki, L. E., Thistlethwaite, L. R., Lewis, A. N., Sallas, C., Srinivasan, R. R., Lei, J. T., Kovačević, V., Obradović, P., Ellis, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105799 · Cited by 38 · see citing works
Self-citation
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Stutheit-Zhao, E. Y., Sanz‐García, E., Liu, Z. A., Wong, D., Marsh, K., Razak, A. R. A., Spreafico, A., Bedard, P. L., Hansen, A. R., Lheureux, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1060 · Cited by 35 · see citing works
Characterisation of cell lines derived from prostate cancer patients with localised disease
Moya, L., Walpole, C., Rae, F., Srinivasan, S., Seim, I., Lai, J., Nicol, D. L., Williams, E. D., Clements, J. A., & Batra, J. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00679-x · Cited by 34 · see citing works
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Mei, J., Liu, X., Tian, H., Chen, Y., Cao, Y., Zeng, J., Liu, Y., Chen, Y., Gao, Y., Yin, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1656 · Cited by 34 · see citing works
Recent advances in breast cancer cell line research
Sharma, M. P., Shukla, S., & Misra, G. (2024) · International Journal of Cancer · doi:10.1002/ijc.34849 · Cited by 33 · see citing works
Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers
Derouane, F., Desgres, M., Moroni, C., Ambroise, J., Berlière, M., Bockstal, M. V., Galant, C., van Marcke, C., Vara-Messler, M., Hutten, S. J., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01788-8 · Cited by 33 · see citing works
Stem Cells and Organoids: A Paradigm Shift in Preclinical Models Toward Personalized Medicine
Luce, E., & Duclos‐Vallée, J. (2025) · Pharmaceuticals · doi:10.3390/ph18070992 · Cited by 33 · see citing works
Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening
Zhang, S., Shen, J., Wang, X., Sun, X., Wu, Y., Zhang, M., Wang, R., & Hu, K. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20230010 · Cited by 33 · see citing works
Patient‐Derived Organoids as Therapy Screening Platforms in Cancer Patients
Khorsandi, D., Yang, J., Foster, S., Khosravi, S., Kouchehbaghi, N. H., Zarei, F., Lee, Y. B., Runa, F., Gangrade, A., Voskanian, L., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302331 · Cited by 31 · see citing works
The Transformative Role of 3D Culture Models in Triple-Negative Breast Cancer Research
Bittman-Soto, X. S., Thomas, E. S., Ganshert, M., Mendez‐Santacruz, L. L., & Harrell, J. C. (2024) · Cancers · doi:10.3390/cancers16101859 · Cited by 31 · see citing works
Three-Dimensional in Vitro Models: A Promising Tool To Scale-Up Breast Cancer Research
Azimian, V., Rafiee, L., Sheikholeslam, M., Shariati, L., Vaseghi, G., Savoji, H., & Javanmard, S. H. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00277 · Cited by 30 · see citing works
Precision oncology: current and future platforms for treatment selection
Tang, X., Berger, M. F., & Solit, D. B. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.009 · Cited by 30 · see citing works
Cancer brain metastasis: molecular mechanisms and therapeutic strategies
Lu, Y., Huang, Y., Zhu, C., Li, Z., Zhang, B., Sheng, H., Li, H., Liu, X., Xu, Z., Wen, Y., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00251-0 · Cited by 29 · see citing works
Self-citation
Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish
Singhal, S. S., Garg, R., Mohanty, A. R., Garg, P., Ramisetty, S. K., Mirzapoiazova, T., Soldi, R., Sharma, S., Kulkarni, P., & Salgia, R. (2023) · Cancers · doi:10.3390/cancers15112961 · Cited by 29 · see citing works
Simultaneous isolation of hormone receptor–positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms
Högström, J., Cruz, K. A., Selfors, L. M., Ward, M. N., Mehta, T. S., Kanarek, N., Philips, J., Dialani, V. M., Wulf, G. M., Collins, L. C., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105021 · Cited by 28 · see citing works
Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening
Choi, S. Y., Shim, J., Gu, D., Kim, S. Y., Kim, H. J., Shin, D., & Chung, M. K. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106571 · Cited by 28 · see citing works
A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine
Kalla, J., Pfneissl, J., Mair, T., Tran, L., & Egger, G. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00960-8 · Cited by 28 · see citing works
The roles of patient‐derived xenograft models and artificial intelligence toward precision medicine
Babu, J. V., ArulJothi, K. N., Mythili, V. M. R., Singh, S. K., Prasher, P., Gupta, G., Dua, K., Rakshith, H. S., Kaliappan, K., & Anand, K. (2024) · MedComm · doi:10.1002/mco2.745 · Cited by 28 · see citing works
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma
Thorel, L., Morice, P., Paysant, H., Florent, R., Babin, G., Thomine, C., Perréard, M., Abeilard, E., Giffard, F., Brotin, É., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02809-8 · Cited by 28 · see citing works
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 27 · see citing works
Patient-derived organoids: a promising tool for breast cancer research
Shi, Y., Guan, Z., Cai, G., Nie, Y., Zhang, C., Luo, W., & Liu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1350935 · Cited by 27 · see citing works
Rat Models of Hormone Receptor-Positive Breast Cancer
Nicotra, R., Lutz, C., Messal, H. A., & Jonkers, J. (2024) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-024-09566-0 · Cited by 26 · see citing works
A review of 3D bioprinting for organoids
Li, Z., Chen, L., Wu, J., Chen, Y., Zhu, Y. Z., Li, G., Xie, G., Tang, G., & Xie, M. (2025) · Medical Review · doi:10.1515/mr-2024-0089 · Cited by 26 · see citing works
Self-citation
Estrogen regulates divergent transcriptional and epigenetic cell states in breast cancer
Ors, A., Chitsazan, A., Doe, A. R., Mulqueen, R. M., Ak, Ç., Wen, Y., Haverlack, S., Handu, M., Naldiga, S., Saldivar, J. C., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac908 · Cited by 26 · see citing works
Selective inhibition of CDK9 in triple negative breast cancer
Mustafa, E. H., Laven‐Law, G., Kikhtyak, Z., Nguyen, V. T. M., Ali, S., Pace, A. A., Iggo, R. D., Kebede, A., Noll, B., Wang, S., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02892-3 · Cited by 27 · see citing works
Modeling lung adenocarcinoma metastases using patient-derived organoids
Liu, Y., Lankadasari, M. B., Rosiene, J. A., Johnson, K. E., Zhou, J., Bapat, S., Chow-Tsang, L.-F., Tian, H., Mastrogiacomo, B., He, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101777 · Cited by 25 · see citing works
Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine
Abbasian, M. H., Sobhani, N., Sisakht, M. M., D’Angelo, A., Sirico, M., & Roudi, R. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10805-4 · Cited by 25 · see citing works
Cryo‐Shocked Tumor‐Reprogrammed Sonosensitive Antigen‐Presenting Cells Improving Sonoimmunotherapy via T Cells and NK Cells Immunity
Qian, X., Yi, W., Yan, W., Cai, Y., Hu, S., Yan, D., Zhao, Z., Li, R. H., Wang, L., Xu, H., et al. (2025) · Advanced Materials · doi:10.1002/adma.202413289 · Cited by 25 · see citing works
A combined enteric neuron-gastric tumor organoid reveals metabolic vulnerabilities in gastric cancer
Chan, B. K. C., Zhang, C., Poon, C. H., Lee, M. H. Y., Chu, H. Y., Wang, B., Chen, S.-G., Yan, H. H. N., Leung, S. Y., & Wong, A. S. L. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.08.006 · Cited by 24 · see citing works
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
Preković, S., Chalkiadakis, T., Roest, M., Roden, D. L., Lutz, C., Schuurman, K. G., Opdam, M., Hoekman, L., Abbott, N., Tesselaar, T., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317737 · Cited by 24 · see citing works
Preclinical Models of Brain Metastases in Breast Cancer
Knier, N. N., Pellizzari, S., Zhou, J., Foster, P. J., & Parsyan, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10030667 · Cited by 22 · see citing works
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer
Echeverria, G. V., Cai, S., Tu, Y., Shao, J., Powell, E., Redwood, A. B., Jiang, Y., McCoy, A., Rinkenbaugh, A. L., Lau, R., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-022-00502-1 · Cited by 22 · see citing works
In vitro co-culture models for studying organoids-macrophages interaction: the golden technology of cancer immunotherapy
Liu, J. (2024) · American Journal of Cancer Research · doi:10.62347/bqfh7352 · Cited by 21 · see citing works
Targeting alternative splicing in cancer immunotherapy
Han, N., & Liu, Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232146 · Cited by 21 · see citing works
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”
Lim, B., Seth, S., Yam, C., Huo, L., Fujii, T., Lee, J., Bassett, R. L., Nasser, S., Ravenberg, L., White, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101595 · Cited by 21 · see citing works
Self-citation
3D Tumor Models for Breast Cancer: Whither We Are and What We Need
Balachander, G. M., Kotcherlakota, R., Nayak, B., Kedaria, D., Rangarajan, A., & Chatterjee, K. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00230 · Cited by 21 · see citing works
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
Soosainathan, A., Iravani, M., Botty, R. E., Alexander, J. J., Sourd, L., Morisset, L., Painsec, P., Orha, R., Nikitorowicz-Buniak, J., Pancholi, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0650 · Cited by 20 · see citing works
Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method
Feng, Q.-S., Shan, X., Yau, V., Cai, Z., & Xie, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010062 · Cited by 20 · see citing works
Rational design matrix materials for organoid development and application in biomedicine
Huang, Y. F., Zhang, X., Zhang, W., Tang, J., & Liu, J. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf038 · Cited by 20 · see citing works
Clinical applications of 3D normal and breast cancer organoids: A review of concepts and methods
Lewis, S. M., Callaway, M. K., & dos Santos, C. O. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221131877 · Cited by 20 · see citing works

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncologyPreprint
Guillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.28.433268 · Cited by 17 · see citing works
Self-citation
Abstract SY16-02: Using patient-derived models for functional precision oncology in advanced breast cancer
Welm, A. L. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-sy16-02
Self-citation
Abstract P3-08-09: Development and molecular characterization of hard-to-treat breast cancer pre-clinical models to enhance precision medicine
Kuasne, H., fortier, A.-M., Busque, S., Mathien, S., Savage, P., Ramirez, C. M., Monast, A., Soleinova, M., Ömeroğlu, A., Asselah, J., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.sabcs22-p3-08-09
The combination of breast cancer PDO and mini‐PDX platform for drug screening and individualized treatment
Cui, Y., Ran, R., Da, Y., Zhang, H., Jiang, M., Qi, X., Zhang, W., Niu, L., Zhou, C., Zhou, C., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18374 · Cited by 14 · see citing works
Abstract 1273: Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery
Trachet, E. E., Holmquist, C., Nagl, S., & Gonzales, P. M. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-1273 · Cited by 1 · see citing works

Authors: Guillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C.-H., Toner, J., Wang, G., Qiao, Y., Huang, X., Greenland, J. A., Vahrenkamp, J. M., Lum, D. H., Factor, R. E., Nelson, E. W., Matsen, C. B., Poretta, J. M., Rosenthal, R., Beck, A. C., Buys, S. S., Vaklavas, C., Ward, J. H., Jensen, R. L., Jones, K. B., Li, Z., Oesterreich, S., Dobrolecki, L. E., Pathi, S. S., Woo, X. Y., Berrett, K. C., Wadsworth, M. E., Chuang, J. H., Lewis, M. T., Marth, G. T., Gertz, J., Varley, K. E., Welm, B. E., & Welm, A. L.
Affiliations: University of Utah (US)
Huntsman Cancer Institute (US)
University of Pittsburgh (US)
Baylor College of Medicine (US)
The Jackson Laboratory for Genomic Medicine (US)
Corresponding author: Welm, Bryan E.
Welm, Alana L.
ORCID: Fujita, Maihi
Scherer, Sandra D.
Bailey, Matthew H.
Chu, Zhengtao
Zhao, Ling
Cortes-Sanchez, Emilio
Huang, Xiaomeng
Vahrenkamp, Jeffery M.
Lum, David H.
Factor, Rachel E.
Nelson, Edward W.
Matsen, Cindy B.
Beck, Anna C.
Buys, Saundra S.
Vaklavas, Christos
Ward, John H.
Jensen, Randy L.
Jones, Kevin B.
Li, Zheqi
Oesterreich, Steffi
Dobrolecki, Lacey E.
Woo, Xing Yi
Berrett, Kristofer C.
Wadsworth, Mark E.
Chuang, Jeffrey H.
Lewis, Michael T.
Gertz, Jason
Varley, Katherine E.
Welm, Bryan E.
Welm, Alana L.
Venue: Nature Cancer
Publisher: Springer Science and Business Media LLC
Published: 2022-02-24
Volume: 3
Issue: 2
Pages: 232-250
ISSN: 2662-1347 (ISSN-L)
DOI: 10.1038/s43018-022-00337-6
PMC: PMC8882468
OpenAlex: W4214507610
Cited by: 416
References: 69
Citations by year: 2026: 87 · 2025: 99 · 2024: 104 · 2023: 78 · 2022: 43 · 2021: 5
FWCI: 33.88
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Cancer (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Digital Commons-TMC (Texas Medical Center) (submittedVersion)
The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders: U.S. Department of Defense (W81XWH1210077, W81XWH1410417)
American Cancer Society (P30 CA042014)
Breast Cancer Research Foundation
Cancer Prevention and Research Institute of Texas (CA125123, RP170691)
University of Utah (P30 CA042014)
Huntsman Cancer Foundation (P30CA042014)
Huntsman Cancer Institute (P30CA042014)
National Institutes of Health (/ NCI R01, CA125123)
National Human Genome Research Institute (T32HG008962)
National Cancer Institute (R01CA221303, NCI-CA125123, CA125123, U01CA217617, U54CA224076, U24CA224067, P30CA042014, P30CA125123)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
Keywords: breast cancer, patient-derived xenografts, organoids, endocrine-resistant breast cancer, metastatic breast cancer, triple-negative breast cancer, precision oncology, drug screening, drug repurposing, treatment-refractory cancer
MeSH terms: Humans, Organoids, United States, Xenograft Model Antitumor Assays, Drug Discovery, Precision Medicine, Heterografts, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks